## Edgar Filing: ADMA BIOLOGICS, INC. - Form 4

ADMA BIOL Form 4										
February 01, 2	Л	STATES			AND EX( , D.C. 20		COMMISSIO		PPROVAL 3235-0287	
Check this if no longe subject to Section 16 Form 4 or Form 5 obligations may contin <i>See</i> Instruct 1(b).	Filed pu Section 17	rsuant to S (a) of the I	F CHAN Section Public U	NGES IN SECUI 16(a) of th Jtility Hol	BENEF RITIES ne Securit lding Con	( <b>CIAL O</b> ) ies Excha	WNERSHIP OF nge Act of 1934, of 1935 or Secti 940	Expires: Estimated burden hou response	urs per	
(Print or Type Ro	esponses)									
1. Name and Address of Reporting Person <u>*</u> Grossman Jerrold B			Symbol		d Ticker or GICS, IN	Trading C. [ADM/	5. Relationship of Reporting Person(s) to Issuer A]			
(Last) C/O ADMA STATE ROU	BIOLOGICS, I	(Middle) NC., 465		of Earliest T Day/Year) 2016	ransaction		(Ch X_ Director Officer (giv below)		e) % Owner her (specify	
(Street) RAMSEY, NJ 07446			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
(City)	(State)	(Zip)	Tak	la I Nan I	Doministry	Soonwition A	Person	of on Donoficio	lly Owned	
1.Title of 2	Transaction Date Month/Day/Year)	-	ed Date, if	3. Transactic Code (Instr. 8)	4. Securiti nAcquired Disposed (Instr. 3, 4	es (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Repo	rt on a separate lin	e for each cl	ass of sec	urities bene	Person inform require	ns who restation cont ation cont ed to resp ys a curre	or indirectly. spond to the collectained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Se

## Edgar Filing: ADMA BIOLOGICS, INC. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8		Acquire (A) or Dispose (D) (Instr. 3 and 5)	d of					C
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Options to purchase	\$ 5.96 <u>(1)</u>	01/28/2016		А		9,000		(2)	01/28/2026	Common Stock	9,000	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationsh		
1	Director	10% Owner	Officer	Other
Grossman Jerrold B C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446	Х			
Signatures				
/s/ Jerrold B. 02/0 Grossman	1/2016			

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The exercise price reflects the per share fair market value of the Company's common stock, as determined by the closing price of the (1) Company's common stock on the NASDAQ Stock Market on January 28, 2016, the date that the option grant was approved by the Company's board of directors.
- (2) These options will vest monthly over a period of 24 months and terminate 12 months following separation.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In